Journal article

Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours

Abstract:: NCT02157792.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Shapiro, G. I., Wesolowski, R., Devoe, C., Lord, S., Pollard, J., Hendriks, B. S., Falk, M., Diaz-Padilla, I., Plummer, R., & Yap, T. A. (2021). Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. British Journal of Cancer, 125(4), 520–527.

MLA Style

Shapiro, GI, et al. “Phase 1 Study of the ATR Inhibitor Berzosertib in Combination with Cisplatin in Patients with Advanced Solid Tumours.” British Journal of Cancer, vol. 125, no. 4, 2021, pp. 520–27.

Chicago Style

Shapiro, GI, R Wesolowski, C Devoe, et al. 2021. “Phase 1 Study of the ATR Inhibitor Berzosertib in Combination with Cisplatin in Patients with Advanced Solid Tumours.” British Journal of Cancer 125 (4): 520–27.
Print

Access Document

Files:: Shapiro_et_al_2021_Phase_1_study.pdf

(Preview, Version of record, pdf, 554.8KB, Terms of use)

Publisher copy:: 10.1038/s41416-021-01406-w

Publication website:: https://discovery.ucl.ac.uk/10184735/1/s41416-023-02542-1%20%281%29.pdf

Authors

+ Shapiro, GI More by this author

Role:: Author
ORCID:: 0000-0002-3331-4095

+ Wesolowski, R More by this author

Role:: Author
ORCID:: 0000-0003-0606-0648

+ Devoe, C More by this author

Role:: Author
ORCID:: 0000-0002-2290-1884

+ Lord, S More by this author

Institution:: University of Oxford
Role:: Author
ORCID:: 0000-0001-7946-5609

+ Pollard, J More by this author

Role:: Author
ORCID:: 0009-0001-7995-9606

More authors...

+ Merck KGaA More from this funder

Funder identifier:: 10.13039/100009945
Grant:: N/A

+ Vertex Pharmaceuticals More from this funder

Funder identifier:: 10.13039/100011022
Grant:: N/A

Publisher:: Springer Nature [academic journals on nature.com]
Journal:: British Journal of Cancer More from this journal
Volume:: 125
Issue:: 4
Pages:: 520-527
Publication date:: 2021-05-26
DOI:: 10.1038/s41416-021-01406-w
EISSN:: 1532-1827
ISSN:: 0007-0920

Language:: English
Keywords:: Medicine

Internal medicine

Adverse effect

Neutropenia

Pharmacodynamics

Biology

Cisplatin

Pharmacokinetics

Refractory (planetary science)

Pharmacology

Chemotherapy

Tolerability
Pubs id:: 1179215
Local pid:: pubs:1179215
Source identifiers:: W3165285070
Deposit date:: 2026-03-24
ARK identifier:: ark:/29072/ora_fa64601aee674cc082321bda525a03d2

Terms of use

Copyright date:: 2021

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP